BeOne Medicines (NASDAQ: ONC) insiders tied to Baker Bros. sell RSU shares for tax withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BeOne Medicines Ltd. insiders linked to Baker Bros. entities reported small share sales tied to RSU vesting and tax withholding. On May 22, 2026, Michael Goller sold 2,743 ordinary shares at $23.8512 per share and Ranjeev Krishana sold 2,756 ordinary shares at $23.7905 per share. Footnotes explain these 5,499 ordinary shares, in the form of 423 American Depositary Shares (ADS), were sold in connection with the vesting of restricted stock units as mandatory tax-withholding transactions, not discretionary open-market selling. The positions are attributed to funds advised by Baker Bros. Advisors LP, which has voting and dispositive power, while Julian and Felix Baker and related entities disclaim beneficial ownership beyond their indirect pecuniary interest. After these transactions, the funds continue to hold large positions, including 8,068,411 ADS and 730,642 ADS reported as indirect holdings.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 10,998 shares ($261,981)
Net Sell
10 txns
Insider
BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN
Role
null | null | null | null | null | null
Sold
10,998 shs ($262K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 2,743 | $23.8512 | $65K |
| Sale | Ordinary Shares | 2,743 | $23.8512 | $65K |
| Sale | Ordinary Shares | 2,756 | $23.7905 | $66K |
| Sale | Ordinary Shares | 2,756 | $23.7905 | $66K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 145,322 shares (Indirect, See Footnotes);
Ordinary Shares — 1 shares (Direct, null);
American Depositary Shares — 10,418 shares (Direct, null);
American Depositary Shares — 730,642 shares (Indirect, See Footnotes)
Footnotes (1)
- On May 22, 2026, Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser") sold 2,743 ordinary shares ("Ordinary Shares"), in the form of 211 American Depositary Shares of the Issuer ("ADS") of BeOne Medicines Ltd. (the "Issuer") at a price of $23.8512 per ordinary share or $310.0659 per ADS and Ranjeev Krishana, a full-time employee of the Adviser sold 2,756 Ordinary Shares in the form of 212 ADS at a price of $23.7905 per ordinary share or $309.2769 per ADS. The Ordinary Shares sold were received from the vesting of restricted stock units (each, an "RSU") that Michael Goller and Ranjeev Krishana were granted on May 21, 2025 as compensation for their service on the board of directors of the Issuer (the "Board"). Such sales were effected in connection with the vesting of such RSUs pursuant to mandatory tax withholding provisions in the applicable RSU award agreements. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in such securities. The Funds (as defined below) each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds (as defined below) and (ii) the Funds (as defined below), Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest). The Adviser serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs. The Ordinary Shares sold and reported on Table I represent a portion of the Ordinary Shares received by each of Michael Goller and Ranjeev Krishana upon vesting of RSUs granted on May 21, 2025. These sales, totaling 2,743 Ordinary Shares (211 ADS) for Michael Goller and 2,756 Ordinary Shares (212 ADS) for Ranjeev Krishana totaling 5,499 Ordinary Shares (423 ADS) in the aggregate, are reported for each of the Funds as each had an indirect proportionate pecuniary interest in such securities. Michael Goller and Ranjeev Krishana serve on the Board as representatives of the Funds and their affiliates and control persons. Includes beneficial ownership of 71,279 Ordinary Shares received from vested RSUs previously granted to Michael Goller, and 71,266 Ordinary Shares received from vested RSUs previously granted to Ranjeev Krishana, in their capacity as directors of the Issuer. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I directly held by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Ordinary Share held directly by Felix J. Baker. Ordinary Share held directly by Julian C. Baker. Each ADS represents 13 Ordinary Shares. American Depositary Shares held directly by Felix J. Baker. American Depositary Shares held directly by Julian C. Baker. As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Key Figures
Goller sale: 2,743 ordinary shares at $23.8512/share
Krishana sale: 2,756 ordinary shares at $23.7905/share
Aggregate RSU shares sold: 5,499 ordinary shares (423 ADS)
+4 more
7 metrics
Goller sale
2,743 ordinary shares at $23.8512/share
Sold on May 22, 2026 from vested RSUs
Krishana sale
2,756 ordinary shares at $23.7905/share
Sold on May 22, 2026 from vested RSUs
Aggregate RSU shares sold
5,499 ordinary shares (423 ADS)
Tax-withholding sales tied to RSU vesting
ADS ratio
1 ADS = 13 ordinary shares
Conversion ratio disclosed in footnote
ADS holding 1
8,068,411 ADS
Indirect holding reported after transactions
ADS holding 2
730,642 ADS
Additional indirect holding reported after transactions
Net shares sold
10,998 shares
Total non-derivative ordinary shares sold per summary
Key Terms
American Depositary Shares, restricted stock units, pecuniary interest, voting and dispositive power, +2 more
6 terms
restricted stock units financial
"The Ordinary Shares sold were received from the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
pecuniary interest financial
"may be deemed to have an indirect pecuniary interest in the Ordinary Shares"
voting and dispositive power financial
"the Adviser has voting and dispositive power over the Share Options, RSUs"
beneficial ownership regulatory
"disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transactions did BeOne Medicines (ONC) report in this Form 4?
The Form 4 reports sales of 2,743 and 2,756 ordinary shares on May 22, 2026. These came from vested restricted stock units for two Baker Bros. Advisors employees serving on BeOne Medicines’ board.
What ongoing BeOne Medicines (ONC) holdings do the Baker Bros.-advised funds report?
After the reported transactions, the filing shows indirect holdings of 8,068,411 American Depositary Shares and 730,642 American Depositary Shares. Footnotes explain these positions are held by funds advised by Baker Bros. Advisors LP, with the adviser having voting and dispositive power.